EU/3/20/2276: Orphan designation for the treatment of retinal detachment



On 4 June 2020, orphan designation EU/3/20/2276 was granted by the European Commission to Helio Vision Germany GmbH, Germany, for methotrexate for the treatment of retinal detachment.

Key facts

Active substance
Intended use
Treatment of retinal detachment
Orphan designation status
EU designation number
Date of designation

Helio Vision Germany GmbH
Wallbrunnstrasse 24
79539 Loerrach
Tel. + 1 78 1761 4904


Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating